Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 27

1.
2.

Increased sialylation of site specific O-glycoforms of hemopexin in liver disease.

Sanda M, Benicky J, Wu J, Wang Y, Makambi K, Ahn J, Smith CI, Zhao P, Zhang L, Goldman R.

Clin Proteomics. 2016 Sep 21;13:24. doi: 10.1186/s12014-016-9125-x. eCollection 2016.

3.

An Open-Label Trial of 12-Week Simeprevir plus Peginterferon/Ribavirin (PR) in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 1 (GT1).

Asselah T, Moreno C, Sarrazin C, Gschwantler M, Foster GR, Craxí A, Buggisch P, Ryan R, Lenz O, Scott J, Van Dooren G, Lonjon-Domanec I, Schlag M, Buti M.

PLoS One. 2016 Jul 18;11(7):e0158526. doi: 10.1371/journal.pone.0158526. eCollection 2016.

4.

Impact of new treatment options for hepatitis C virus infection in liver transplantation.

Righi E, Londero A, Carnelutti A, Baccarani U, Bassetti M.

World J Gastroenterol. 2015 Oct 14;21(38):10760-75. doi: 10.3748/wjg.v21.i38.10760. Review.

5.

Promotion of Cancer Stem-Like Cell Properties in Hepatitis C Virus-Infected Hepatocytes.

Kwon YC, Bose SK, Steele R, Meyer K, Di Bisceglie AM, Ray RB, Ray R.

J Virol. 2015 Nov;89(22):11549-56. doi: 10.1128/JVI.01946-15. Epub 2015 Sep 9.

6.

Therapy of Delta Hepatitis.

Yurdaydin C, Idilman R.

Cold Spring Harb Perspect Med. 2015 Aug 7;5(10). pii: a021543. doi: 10.1101/cshperspect.a021543. Review.

7.

Management of hepatitis C infection before and after liver transplantation.

Fagiuoli S, Ravasio R, Lucà MG, Baldan A, Pecere S, Vitale A, Pasulo L.

World J Gastroenterol. 2015 Apr 21;21(15):4447-56. doi: 10.3748/wjg.v21.i15.4447. Review.

8.

Post-transplant survival is improved for hepatitis C recipients who are RNA negative at time of liver transplantation.

Fortune BE, Martinez-Camacho A, Kreidler S, Gralla J, Everson GT.

Transpl Int. 2015 Aug;28(8):980-9. doi: 10.1111/tri.12568. Epub 2015 Apr 16.

9.

Predictors of response to 24-week telaprevir-based triple therapy for treatment-naïve genotype 1b chronic hepatitis C patients.

Abe H, Tsubota A, Shimada N, Atsukawa M, Kato K, Takaguchi K, Asano T, Chuganji Y, Sakamoto C, Toyoda H, Kumada T, Ide T, Sata M, Aizawa Y.

Gastroenterol Res Pract. 2014;2014:549709. doi: 10.1155/2014/549709. Epub 2014 Aug 14.

10.

Processes to manage analyses and publications in a phase III multicenter randomized clinical trial.

Snow KK, Bell MC, Stoddard AM, Curto TM, Wright EC, Dienstag JL.

Trials. 2014 May 7;15:159. doi: 10.1186/1745-6215-15-159.

11.

Individualization of chronic hepatitis C treatment according to the host characteristics.

Gatselis NK, Zachou K, Saitis A, Samara M, Dalekos GN.

World J Gastroenterol. 2014 Mar 21;20(11):2839-53. doi: 10.3748/wjg.v20.i11.2839. Review.

12.

Non-invasive prediction of hepatic fibrosis in patients with chronic HCV based on the routine pre-treatment workup.

Khairy M, Abdel-Rahman M, El-Raziky M, El-Akel W, Zayed N, Khatab H, Esmat G.

Hepat Mon. 2012 Nov;12(11):e6718. doi: 10.5812/hepatmon.6718. Epub 2012 Nov 1.

13.

The practical management of treatment failure in chronic hepatitis C: a summary of current research and management options for refractory patients.

Hassanein T, Shiffman ML, Zein NN.

Gastroenterol Hepatol (N Y). 2007 Jun;3(6 Suppl 20):4-32. No abstract available.

14.

A randomized controlled trial of pretransplant antiviral therapy to prevent recurrence of hepatitis C after liver transplantation.

Everson GT, Terrault NA, Lok AS, Rodrigo del R, Brown RS Jr, Saab S, Shiffman ML, Al-Osaimi AM, Kulik LM, Gillespie BW, Everhart JE; Adult-to-Adult Living Donor Liver Transplantation Cohort Study.

Hepatology. 2013 May;57(5):1752-62. doi: 10.1002/hep.25976. Epub 2013 Jan 17.

15.

SRM targeted proteomics in search for biomarkers of HCV-induced progression of fibrosis to cirrhosis in HALT-C patients.

Qin S, Zhou Y, Lok AS, Tsodikov A, Yan X, Gray L, Yuan M, Moritz RL, Galas D, Omenn GS, Hood L.

Proteomics. 2012 Apr;12(8):1244-52. doi: 10.1002/pmic.201100601.

16.

Randomized trial comparing dose reduction and growth factor supplementation for management of hematological side effects in HIV/hepatitis C virus patients receiving pegylated-interferon and ribavirin.

Talal AH, Liu RC, Zeremski M, Dimova R, Dove L, Pearce D, Hassanein T, Doonquah L, Aboulafia D, Rodriguez J, Bonilla H, Galpin J, Aberg JA, Johnston B, Glesby MJ, Jacobson IM.

J Acquir Immune Defic Syndr. 2011 Nov 1;58(3):261-8. doi: 10.1097/QAI.0b013e3182324af9.

17.

Mallory-Denk bodies are associated with outcomes and histologic features in patients with chronic hepatitis C.

Rakoski MO, Brown MB, Fontana RJ, Bonkovsky HL, Brunt EM, Goodman ZD, Lok AS, Omary MB; HALT-C Trial Group.

Clin Gastroenterol Hepatol. 2011 Oct;9(10):902-909.e1. doi: 10.1016/j.cgh.2011.07.006. Epub 2011 Jul 23.

18.

Predicting the probable outcome of treatment in HCV patients.

Navaneethan U, Kemmer N, Neff GW.

Therap Adv Gastroenterol. 2009 Sep;2(5):287-302. doi: 10.1177/1756283X09339079.

19.

Very-Low-Dose Pegylated Interferon a2a Plus Ribavirin Therapy for Advanced Liver Cirrhosis Type C: A Possible Therapeutic Alternative without Splenic Intervention.

Ohkoshi S, Yamagiwa S, Yano M, Takahashi H, Aoki YH, Matsuda Y, Aoyagi Y.

Case Rep Gastroenterol. 2010 Jul 28;4(2):261-266.

20.

Treatment options for HCV nonresponders and relapse patients.

Pearlman BL, Sjogren MH.

Gastroenterol Hepatol (N Y). 2010 Mar;6(3 Suppl 6):1-12.

Supplemental Content

Support Center